Status:
RECRUITING
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborating Sponsors:
University of Lisbon
Sahlgrenska University Hospital
Conditions:
Cerebral Venous Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Patients with cerebral venous thrombosis (CVT) are currently treated with anticoagulants during 3-12 months after diagnosis, to prevent worsening of the CVT and recurrent thrombosis, and to...
Eligibility Criteria
Inclusion
- Written informed consent for the use of observational data
- Age \>18 years at the time of CVT diagnosis
- Radiologically confirmed CVT diagnosis (CT-venography, MRI or catheter angiography)
- Oral anticoagulant treatment (DOAC or VKA) started within 30 days of CVT diagnosis (patient may initially be treated with heparin)
- Inclusion in the study within 90 days of CVT diagnosis
Exclusion
- Anticoagulant treatment at the time of CVT diagnosis
- Pregnancy or lactation (post-partum women are eligible if they do not give breast-feeding)
- Mechanical heart valve
- Severe renal insufficiency (defined as an eGFR \<15 ml/min)
- Severe liver disease resulting in clinically relevant coagulopathy
Key Trial Info
Start Date :
January 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT04660747
Start Date
January 27 2021
End Date
January 1 2028
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jonathan Coutinho
Amsterdam, North Holland, Netherlands, 1105AZ